Lomond Therapeutics Completes Second and Third Closings and adds Two New Investors — Lomond Therapeutics
Summary
D.Phil., co-founder and chief executive officer at Lomond Therapeutics.This transaction provides the additional resources necessary to advance our potentially best-in-class or first-in-class programs, lomonitinib, lonitoclax and our menin inhibitor, through clinical development. Lomond Therapeutics goal is to utilize its capabilities and platform to become a leader in developing novel breakthrough medicines to maximize the clinical benefit when treating hematologic malignancies. Existing FLT3 inhibitors are limited by the emergence of resistance mutations or escape pathways, lack of selectivity and safety profile, as clinical data have demonstrated their inability to inhibit disease progression. Compared to venetoclax, lonitoclax exhibits significantly less suppression of non-malignant immune cell populations, a result that suggests superior selectivity and an improved safety profile. In the second half of 2025, we expect to select one of the menin inhibitors as a candidate for further preclinical study and, if the results are supportive, potentially clinical study.This press release contains forward-looking statements.